Search Technologies

Researchers at the National Cancer Institute (NCI) developed novel analogs of the natural product schweinfurthins to treat neurofibromatosis type 1 (NF1). The compounds demonstrate effective growth inhibition in malignant peripheral nerve sheath tumor cell lines and mouse models of astrocytomas. Researchers seek licensing and/or co-development research collaboration opportunities to further develop the schweinfurthin analogs.

The National Institute of Health, National Cancer Institute is seeking parties interested in licensing a marker for predicting taxane chemotherapy outcome.

The National Cancer Institute, Laboratory of Molecular Biology seeks parties to co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers.

Investigators at the National Cancer Institute have discovered fluoroquinolone derivatives as specific Tdp1 inhibitors that could potentiate the pharmacological action of Top1 inhibitors currently used in cancer treatment.

Chimeric Antigen Receptors (CARs) are engineered proteins that can be used in a therapeutic capacity when expressed by an immune cell (e.g., a T cell). Specifically, CARs comprise a targeting domain (such as an antibody or binding fragment thereof) as well as domains that activate immune cells. By selecting a targeting domain that binds to a protein that is selectively expressed on a cancer cell, it is possible to target immune cells to the cancer cells. Upon binding to the target cell, the immune cells are activated, leading to the destruction of the cancer cell. This therapeutic approach holds great promise, as evidenced by the recent FDA-approval of CAR-T cell therapies, KYMRIAH and YESCARTA, both of which target CD19.

The National Cancer Institute seeks parties interested licensing or collaborative research to co-develop thalidomide analogs to treat cancer and inflammatory diseases.

Researchers at the National Cancer Institute have discovered small molecule inhibitors of Chk2 for the treatment of cancer.

The National Cancer Institute seeks parties interested to license a method to generate RNA molecules suitable for nanoparticle and biomedical applications.

Researchers at the National Eye Institute (NEI) have generated Induced Pluripotent Stem Cells (iPS) from two Late-Onset Reginal (L-ORD) patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. All iPS cells were differentiated into authenticated Retinal Pigment Epithelium (RPE) cells. The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration.